Get the Stockscreener App
23.34
1.66%
0.38
Pre-market:
23.34
Assembly Biosciences Inc stock is traded at $23.34, with a volume of 173.21K.
It is up +1.66% in the last 24 hours and down -18.53% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
See More
Previous Close:
$22.96
Open:
$23.67
24h Volume:
173.21K
Relative Volume:
1.24
Market Cap:
$462.53M
Revenue:
$71.10M
Net Income/Loss:
$-6.38M
P/E Ratio:
-19.44
EPS:
-1.2009
Net Cash Flow:
$-39.84M
1W Performance:
+3.48%
1M Performance:
-18.53%
6M Performance:
-32.54%
1Y Performance:
+38.52%
1-Day Range:
$23.07
$24.15
1-Week Range:
$21.80
$24.15
52-Week Range:
$16.50
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
23.34 | 462.53M | 71.10M | -6.38M | -39.84M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Guggenheim | Buy |
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
ASMB Maintained by Mizuho -- Price Target Raised to $45 - GuruFocus
Assembly Biosciences eyes Gilead HSV plan as ABI-6250 liver pipeline expands - MSN
ASMB SEC FilingsAssembly Bioscie 10-K, 10-Q, 8-K Forms - Stock Titan
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead - MarketBeat
(ASMB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Assembly Biosciences Expands Equity Plans, Reelects Board - TipRanks
Assembly Biosciences (ASMB) CMO awarded 14,000-share RSU-based stock grant - Stock Titan
Assembly Biosciences (ASMB) CMO awarded 14,000 restricted stock units - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) awards 8,000 stock options to director McHutchison - Stock Titan
Assembly Biosciences (ASMB) director receives grant of 8,000 stock options - Stock Titan
Director at Assembly Biosciences (ASMB) receives grant of 8,000 stock options - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) director receives 8,000 stock options grant - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) director receives grant of 8,000 stock options - Stock Titan
Director at Assembly Biosciences (NASDAQ: ASMB) receives 8,000 options - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) PFO awarded 3,500 RSUs - Stock Titan
Assembly Biosciences (ASMB) CSO granted 14,000 RSUs tied to plan amendment - Stock Titan
Assembly Biosciences (ASMB) CEO receives 50,750 RSUs in equity grant - Stock Titan
Assembly Biosciences (ASMB) shareholders back directors, equity plan and ESPP share hikes - Stock Titan
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands - Yahoo Finance
Assembly Biosciences synthesizes new anti-cytomegalovirus agents - BioWorld News
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Biosciences Inc. - GuruFocus
Assembly Biosciences Announces Upcoming Investor Conference Presentations - The Manila Times
ASMB Reiterated by Guggenheim -- Price Target Maintained at $43 - GuruFocus
Biotech Assembly Bio set for June Jefferies, Goldman investor chats - Stock Titan
Assembly Biosciences (ASMB) Holds Steady Near Resistance as Biotech Sector WatchesSector ETF Flow - The Legal Advocate
How (ASMB) Movements Inform Risk Allocation Models - Stock Traders Daily
Gilead boosts Assembly Biosciences (NASDAQ: ASMB) ownership to 25.1% of shares - Stock Titan
Gilead adds Assembly Biosciences (ASMB) shares through new stock grant - Stock Titan
Assembly Biosciences (ASMB) Declines 4.7% as Stock Tests Key Support Near $26PCR Moving Average - newsline.com
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
Assembly Biosciences closes $115 million stock offering - Investing.com UK
Assembly Biosciences closes $115 million stock offering By Investing.com - Investing.com South Africa
Assembly Biosciences Completes Significant Equity Offering Financing - TipRanks
Assembly Biosciences (ASMB) completes $115M stock and pre-funded warrant sale - Stock Titan
Assembly Bio raises $115M for viral and liver drug clinical work - Stock Titan
Assembly Biosciences Surges 6.9% as Buyers Defend Key Support Level (ASMB)High Dividend Factor - The Legal Advocate
Assembly Biosciences prices $100M equity offering - MSN
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday - Sahm
Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC - TradingView
Assembly Biosciences (NASDAQ: ASMB) raises ~$93M; 3.36M shares, 415K pre-funded warrants - Stock Titan
Assembly Biosciences (ASMB) Expands Clinical Focus on Liver Dise - GuruFocus
Assembly Biosciences (ASMB) Prices $100M Offering to Support Cli - GuruFocus
Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering - Stock Titan
Assembly Biosciences prices $100 million stock offering at $26.50 - Investing.com UK
Assembly Biosciences Expands ABI-6250 Clinical Development to Target Cholestatic Liver Diseases Including PBC and PSC - Minichart
Assembly Biosciences expands ABI-6250 development to liver diseases By Investing.com - Investing.com Nigeria
Assembly Biosciences expands ABI-6250 development to liver diseases - Investing.com UK
Assembly Biosciences prices $100 million stock offering at $26.50 By Investing.com - Investing.com South Africa
Assembly Biosciences prices $100 million offering - The Pharma Letter
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):